A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study.
Phospholipase A2 hydrolyzes membrane phospholipids releasing arachidonic acid and lysophospholipids. These are key precursors of inflammatory mediators, such as prostaglandins, leukotrienes, thromboxanes and PAF, in numerous inflammatory/allergic diseases, including skin inflammation. Accordingly, inhibition of PLA2 has long been postulated as a potentially potent anti-inflammatory therapy. In the present study we tested the effect of a novel PLA2 inhibitor on contact dermatitis in human subjects. A double-blind, placebo-controlled pilot study was conducted on contact dermatitis patients (n = 11) treated with the inhibitor-containing topical preparation (1% cream). Disease severity was assessed by physicians assessment before treatment (day 0) as well as after 14-days and 30-days. Patients treated with 1% PLA2 inhibitor-containing cream showed a 69.9% reduction in disease score while placebo-treated patients showed a reduction of 36.5% with p = 0.0024. The clear improvement in the disease score of inhibitor-treated patients supports the involvement of PLA2 activity in skin inflammation and the therapeutic prospective of its inhibition.
Ingber
A
A
Cohen
Y
Y
Krimsky
M
M
Yedgar
S
S
D000287:Administration, Topical; D000328:Adult; D002626:Chemistry, Pharmaceutical; D003877:Dermatitis, Contact / Q000188:drug therapy*; D004311:Double-Blind Method; D004485:Eczema / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use; D008875:Middle Aged; D010714:Phosphatidylethanolamines / Q000627:therapeutic use; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D010865:Pilot Projects
D004791:Enzyme Inhibitors; D010714:Phosphatidylethanolamines; D006820:Hyaluronic Acid; D010741:Phospholipases A; D054467:Phospholipases A2